Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped
As Arbitration Disappoints
The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.
You may also be interested in...
Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa
The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.